Pricing Log in Create free account
Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

60.58 2.60 +4.48%
Market cap
$8.9B
P/E
19.1×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

TG Therapeutics, Inc. (TGTX) SEC filings, changes and red flags

Red flags

  • Material weakness

    TG Therapeutics, Inc.’s 10-Q reports a material weakness in internal control over financial reporting

    Other than the steps to remediate the material weakness discussed above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

    10-Q filed · The filing · sec.gov

  • Profit ahead of cash

    TG Therapeutics, Inc.’s net income ran ahead of its operating cash flow for a second year, by 44.4% of total assets

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 35 added · 4 removed · 19 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 11, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 3, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 27, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 18, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 16 added · 19 removed · 29 modified
1A: 23 added · 11 removed · 105 modified
7: 54 added · 22 removed · 29 modified 		Profit ahead of cash
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Mar 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024 Material weakness
8-K Nov 4, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 2, 2024 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 28, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.